Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AE, AEs, Amylin, apportionment, attained, attaining, attestation, banned, Belarusian, boundary, camptothecin, Catalyst, Chinese, cleavable, commodity, condensed, Connecticut, corruption, creation, Crimea, deadline, decree, deprioritize, deprioritized, Donetsk, economy, effectuated, Elan, Eli, encoding, energy, espionage, expedient, febrile, forensic, fulfill, futility, Grantback, hand, HHS, IFN, ImmunityBio, inflation, instability, Intelligence, Interbank, intermediate, investor, IO, ipilumamb, Jazz, Lilly, lipid, Luhansk, media, messenger, Moderna, ModernaTX, motion, mRNA, nanoparticle, obfuscate, Onyx, opposed, outflow, outpace, overstatement, penalize, perspective, platinum, Portola, pralauzatamab, praluzatamb, PSU, radiographic, radiology, reallocated, Regeneron, reinstatement, Republic, Rescue, resurgence, retaliation, revert, RNA, Russian, sanction, sectoral, separatist, snapshot, SWIFT, Switzerland, tailored, timeframe, topline, Tranche, Ukraine, understatement, unfriendly, unlicensed, unlock, unselected, Utah
Removed:
abdominal, absolute, aggressive, allocate, alongside, alpha, amortize, Amunix, Amy, anal, appetite, arthralgia, ASCO, asthenia, atezolizumab, autoimmunity, avelumab, Bavencio, behavioral, block, blockade, book, cashflow, cemiplimab, Century, chemotherapy, Chiron, collaborated, constipation, construed, COSO, cough, cut, death, Deficient, deposit, desirable, diagnosed, Directive, discriminate, display, disregarded, draft, durvalumab, dyspnea, edema, elicited, England, ePrivacy, forfeiture, franchise, furnished, headache, Imfinzi, infection, integrin, involuntarily, Jagged, JRC, JSC, Keytruda, killing, Libtayo, Maxygen, maytansinoid, Medivation, microtubule, misstated, modifying, mTOR, multispecific, musculoskeletal, mutational, nominate, online, opdivo, optionee, pain, Pandion, PDC, pembrolizumab, peripheral, Peterson, presence, proving, pyrexia, quickly, rash, recourse, refundable, regression, remedy, removing, renowned, representing, repurchase, respiratory, serine, simplify, Simplifying, strict, studying, synergistic, systemically, Tecentriq, translation, underpayment, unvested, uPA, upper, urinary, vomiting, web, women
Filing tables
Filing exhibits
Associated CTMX transcripts
CTMX similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1)
Registration Statement on Form S-3 No. 333-258510 and related prospectus of CytomX Therapeutics, Inc., and
(2)
Registration Statements (Form S-8 Nos. 333-207694, 333-209992, 333-215795, 333-223491, 333-229916, 333-236711, 333-253452, 333-255832, and 333-263321) pertaining to the 2015 Equity Incentive Plan, the Employee Stock Purchase Plan and the 2019 Employment Inducement Incentive Plan, of CytomX Therapeutics, Inc.;
of our report dated March 27, 2023, with respect to the financial statements of CytomX Therapeutics, Inc., included in this Annual Report (Form 10-K) of CytomX Therapeutics Inc., for the year ended December 31, 2022.
/s/ Ernst & Young LLP
San Jose, California
March 27, 2023